Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bertz

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
International Journal of Pharmaceutics|November 24, 1999
Pulmonary delivery of a dopamine D-1 agonist, ABT-431, in dogs and humansY Zheng, K C Marsh, R J Bertz, et al.
Acta Dermato-Venereologica|January 1, 1991
Incidence and mortality of malignant melanoma in Berlin (West) from 1980 to 1986C Garbe, S Thiess, F Nürnberger, et al.
Journal of Clinical Psychopharmacology|April 22, 1999
Alprazolam increases dehydroepiandrosterone concentrationsP D Kroboth, F S Salek, R A Stone, et al.
Pharmacotherapy|March 5, 2013
Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïveRichard J Bertz, Anna Persson, Ellen Chung, et al.
Journal of Clinical Psychopharmacology|August 1, 1995
Triazolam pharmacokinetics after intravenous, oral, and sublingual administrationP D Kroboth, J W McAuley, F J Kroboth, et al.
Headache|November 7, 2024
Comparative bioavailability of single-dose zavegepant during and between migraine attacks: A phase 1, randomized, open-label, fixed-sequence, two-period studyRichard J Bertz, Julie L Collins, Jennifer Madonia, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 6, 2015
Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjectsTomomi Shiozaki, Takayo Ueno, Hirotaka Nagashima, et al.
AIDS Research and Human Retroviruses|October 31, 2003
Protein binding in antiretroviral therapiesMarta Boffito, David J Back, Terrence F Blaschke, et al.
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|October 22, 2011
[The (German) Center for Cancer Registry Data (ZfKD) at the Robert Koch Institute (RKI) in Berlin]U Wolf, B Barnes, J Bertz, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis CTimothy Eley, Bing He, Shu-Pang Huang, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
International Journal of Pharmaceutics|November 24, 1999
Pulmonary delivery of a dopamine D-1 agonist, ABT-431, in dogs and humansY Zheng, K C Marsh, R J Bertz, et al.
Acta Dermato-Venereologica|January 1, 1991
Incidence and mortality of malignant melanoma in Berlin (West) from 1980 to 1986C Garbe, S Thiess, F Nürnberger, et al.
Journal of Clinical Psychopharmacology|April 22, 1999
Alprazolam increases dehydroepiandrosterone concentrationsP D Kroboth, F S Salek, R A Stone, et al.
Pharmacotherapy|March 5, 2013
Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïveRichard J Bertz, Anna Persson, Ellen Chung, et al.
Journal of Clinical Psychopharmacology|August 1, 1995
Triazolam pharmacokinetics after intravenous, oral, and sublingual administrationP D Kroboth, J W McAuley, F J Kroboth, et al.
Headache|November 7, 2024
Comparative bioavailability of single-dose zavegepant during and between migraine attacks: A phase 1, randomized, open-label, fixed-sequence, two-period studyRichard J Bertz, Julie L Collins, Jennifer Madonia, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 6, 2015
Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjectsTomomi Shiozaki, Takayo Ueno, Hirotaka Nagashima, et al.
AIDS Research and Human Retroviruses|October 31, 2003
Protein binding in antiretroviral therapiesMarta Boffito, David J Back, Terrence F Blaschke, et al.
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|October 22, 2011
[The (German) Center for Cancer Registry Data (ZfKD) at the Robert Koch Institute (RKI) in Berlin]U Wolf, B Barnes, J Bertz, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis CTimothy Eley, Bing He, Shu-Pang Huang, et al.
Pageof 6